Claims against Janssen Pharmaceuticals over the efficacy of the blood thinner Xarelto will be wrapped into Philadelphia's existing mass tort that focuses on claims the drug led to excessive bleeding, under a court order issued Wednesday.

Philadelphia Court of Common Pleas Judge Arnold New issued a case management order transferring Mothena v. Janssen Research & Development to the Xarelto mass tort. The one-page order granted Janssen's October petition asking the court to transfer the case.

The Mothena case alleged novel claims that the once-daily dosing of the drug failed to protect against stroke for 24 hours, and was filed outside the existing mass-tort program, which focuses on allegations that the drug caused uncontrolled bleeding.